1. Home
  2. BCDA vs ULY Comparison

BCDA vs ULY Comparison

Compare BCDA & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • ULY
  • Stock Information
  • Founded
  • BCDA N/A
  • ULY 2013
  • Country
  • BCDA United States
  • ULY United States
  • Employees
  • BCDA N/A
  • ULY N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • ULY
  • Sector
  • BCDA Health Care
  • ULY
  • Exchange
  • BCDA Nasdaq
  • ULY Nasdaq
  • Market Cap
  • BCDA 7.9M
  • ULY 6.7M
  • IPO Year
  • BCDA N/A
  • ULY N/A
  • Fundamental
  • Price
  • BCDA $2.84
  • ULY $0.53
  • Analyst Decision
  • BCDA Strong Buy
  • ULY Strong Buy
  • Analyst Count
  • BCDA 1
  • ULY 1
  • Target Price
  • BCDA $25.00
  • ULY $1.50
  • AVG Volume (30 Days)
  • BCDA 58.1K
  • ULY 58.2K
  • Earning Date
  • BCDA 03-26-2025
  • ULY 03-13-2025
  • Dividend Yield
  • BCDA N/A
  • ULY N/A
  • EPS Growth
  • BCDA N/A
  • ULY N/A
  • EPS
  • BCDA N/A
  • ULY 7.18
  • Revenue
  • BCDA $71,000.00
  • ULY $155,926,000.00
  • Revenue This Year
  • BCDA N/A
  • ULY N/A
  • Revenue Next Year
  • BCDA N/A
  • ULY $4.29
  • P/E Ratio
  • BCDA N/A
  • ULY $0.07
  • Revenue Growth
  • BCDA N/A
  • ULY N/A
  • 52 Week Low
  • BCDA $1.63
  • ULY $0.41
  • 52 Week High
  • BCDA $8.85
  • ULY $3.45
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 67.71
  • ULY 53.89
  • Support Level
  • BCDA $2.27
  • ULY $0.48
  • Resistance Level
  • BCDA $2.78
  • ULY $0.54
  • Average True Range (ATR)
  • BCDA 0.26
  • ULY 0.04
  • MACD
  • BCDA 0.04
  • ULY 0.00
  • Stochastic Oscillator
  • BCDA 86.90
  • ULY 74.95

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and lead to long wait times. Urgently offers an innovative alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

Share on Social Networks: